A new personalized therapy through genomic profiling may improve survival in patients with cancer of unknown primary
The CUPISCO study, the largest to date on cancer of unknown primary, reveals that molecularly guided therapy is more effective than standard chemotherapy in cancer cases with an unfavorable prognosis.